David Muirhead

Pfizer (United Kingdom)

Papers

1

Total Citations

127

H-Index

1

About

David Muirhead is a leading figure in translational bioanalytical chemistry, with a research focus that bridges protein biochemistry and mass spectrometry to advance therapeutic development. His most cited work, a 2012 study on sequential protein and peptide immunoaffinity capture for quantifying human β-nerve growth factor (NGF), exemplifies his major contribution: pioneering hybrid methods that combine immunoaffinity enrichment with mass spectrometry for precise, sensitive quantification of low-abundance proteins in complex biological matrices. This approach has been critical for supporting clinical trials of biologics, such as tanezumab—a humanized monoclonal antibody targeting NGF for chronic pain treatment. With over 127 citations, this paper underscores his impact on the field of targeted proteomics and biomarker validation. Muirhead’s work is notable for its direct application to drug development, enabling researchers to monitor therapeutic targets and pharmacokinetics with unprecedented accuracy. His achievements reflect a career dedicated to solving real-world challenges in bioanalysis, making him a key resource for students and researchers interested in the intersection of analytical chemistry, protein science, and pharmaceutical innovation.

Research Focus

Key Achievements

1
H-Index
1
Papers
127
Total Citations
127
Avg Citations/Paper
🏆 Most Cited Paper
Sequential Protein and Peptide Immunoaffinity Capture for Mass Spectrometry-Based Quantification of Total Human β-Nerve Growth Factor
127 citations · 2012
📈 Most Prolific Year: 2012 (1 Papers)
🤝 Key Collaborators: 5
🏛 Institutions: Pfizer (United Kingdom)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago